Sign in
Not yet taking people in South KoreaNo phase

Lecanemab for people with Parkinson's disease who also have Alzheimer's-type amyloid in the brain

Tests lecanemab in people with Parkinson's disease and amyloid buildup in the brain.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
Status
Not yet recruiting
People taking part
60 people, planned
Started
May 2026
Expected to end
Nov 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lecanemab
  • Lecanemab non-administration group
Record updated
22 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Parkinson's disease who also have amyloid in the brain and mild memory or thinking problems or early dementia.

Age
50 to 90 years
Sex
All sexes
Disease stage
Parkinson's disease with mild cognitive impairment or early dementia (CDR 0.5 or 1) on thinking tests.
Biomarker or test result
Amyloid deposits in the brain confirmed by FBB PET scan.

Main reasons for not taking part

  • Lecanemab cannot be given safely (contraindicated)
  • Another brain disease besides Parkinson's disease or Alzheimer's disease is suspected

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients diagnosed with Parkinson's disease
  • Amyloid deposition confirmed by FBB PET
  • Mild cognitive impairment or early dementia (CDR 0.5 or 1) on neuropsychological tests
  • Adults aged 50-90 years

Who cannot take part

  • Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association)
  • Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 90 years old?

Where in South Korea

  • Yonsei University College of MedicineSeoul, South KoreaContact: Phil Hyu Lee, MDNot yet recruiting

About the trial

What the trial wants to find out

This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and in South Korea in May 2024, as a disease-modifying therapy based on its clinical efficacy and reduction of amyloid plaques in patients with early-stage Alzheimer's disease (AD). AD pathology is also common in PD, and approximately 35% of patients with PD dementia have co-existing AD pathology. Currently, no mediations have been developed to slow the progression of PD. Therefore, this study aimed to determine whether reducing the amyloid burden in patients with PD with co-exsistent AD pathology could potentially slow disease progression. To test it, patients with PD with mild cognitive impairment or early dementia, who were confirmed to have amyloid deposition through amyloid imaging, would be enrolled as a treatment arm, and the degree of reduction of amyloid plaque after 18 months of lecanemab administration would be investigated.

The 2 groups in the trial

  • Lecanemab admnistration groupTreatment being tested

    Patients who receive lecanemab 10mg/kg every two weeks for 18 months

    Treatment: Lecanemab

  • Lecanemab non-admnistration groupExisting treatment, for comparison

    Patients who do not receive lecanemab

    Treatment: Lecanemab non-administration group

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Lecanemab in Patients With Parkinson's Disease With Coexistent Alzheimer's Disease
Plain-language title
Lecanemab for people with Parkinson's disease who also have Alzheimer's-type amyloid in the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Fit questions
Built from NCT07544953, who can take part
Record updated
22 April 2026